Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZR-MD-001 for Contact Lens Discomfort
NCT05548491Phase 2Completed
- Sponsor
- Azura Ophthalmics
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of selenium sulfide ophthalmic ointment in Contact lens discomfort (CLD), meibomian gland dysfunction (MGD), sponsored by Azura Ophthalmics. Started Nov 2022; status: completed.
02
Drugs
selenium sulfide ophthalmic ointment
03
Conditions
Contact lens discomfort (CLD)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT05548491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548491.